Kancera AB (publ)
SSE:KAN.ST
4.09 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kancera AB (publ) |
Symbool | KAN.ST |
Munteenheid | SEK |
Prijs | 4.095 |
Beurswaarde | 333,766,251 |
Dividendpercentage | 0% |
52-weken bereik | 2.22 - 6.77 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Thomas Olin Ph.D. |
Website | https://www.kancera.com |
An error occurred while fetching data.
Over Kancera AB (publ)
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)